The Ohio State University pancreatic disorders network (OSU-PDN)

俄亥俄州立大学胰腺疾病网络 (OSU-PDN)

• 批准号: 9987079
• 负责人: DARWIN LEWIS CONWELL
• 金额: $ 28.83万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9987079
• 关键词: ANXA5 gene; Abdominal Pain; Address; Adult; Biological Markers; Blood; Brittle diabetes; Childhood; Clinical; Clinical Cancer Center; Clinical Research; Clinical Sciences; Collaborations; Consult; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Digestive System Disorders; Disease; Disease Progression; Early Diagnosis; Fibrosis; Funding; Gastroenterologist; Gastroenterology; Goals; Individual; Inflammation; Institution; Knowledge; Left; Liquid substance; Main pancreatic duct; Malignant Neoplasms; Malignant neoplasm of pancreas; Malnutrition; Medical; Medical Research; Medical center; Methods; Modernization; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Ohio; Operative Surgical Procedures; Organ; Pancreas; Pancreatic Diseases; Pancreatic Polypeptide; Participant; Patient Triage; Patients; Pediatric Research; Peptides; Performance; Primary Care Physician; Proteins; Proteome; Proteomics; Protocols documentation; Publishing; Research; Research Infrastructure; Research Proposals; Resources; Risk; Secondary to; Serum; Services; Standardization; Testing; Translational Research; United States; United States National Institutes of Health; Universities; Urine; Validation; accurate diagnosis; base; biomarker panel; candidate marker; chronic pancreatitis; cohort; diagnostic biomarker; early detection biomarkers; pancreatic juice; programs; repository; research study; response; sample collection; translational study

Project Summary and Abstract (Initial Submission) The diagnosis of chronic pancreatitis and T3cDM remain two of the greatest challenges and unmet needs in modern gastroenterology. The focus of this U01 application from The Ohio State University is to form a strategic alliance among academic institutions in the United States. Our major goals are to address the research objectives and aims of the Consortium, and to be considered as a clinical center. Specifically, we a) describe The Ohio State University Pancreatic Disorders Network (OSU-PDN), b) propose two research studies for consideration by the Consortium and c) outline our clinical and translational research infrastructure. Several key experimental observations from our group in CP and T3cDM warrant confirmation [OSU- PDN] and validation [CSCPDPC-CCs] : 1) Proteomic analysis of pancreas fluid (PF) and urine (U) in CP subjects revealed statistically significant fold-changes in several pancreatic fluid proteins - SERPINA5, ANXA5, CST3 (candidate pancreatic fluid markers) and urine proteins - CPN2, A1AG1, AMYP (candidate urine markers) when compared to healthy controls and 2) A significant difference in serum pancreatic polypeptide response to a mixed meal was observed that may distinguish T3cDM from the much more prevalent T2DM. These preliminary observations are the focus of our research proposals for consideration by the Consortium Steering Committee. Our Clinical Center will be centrally coordinated by the Ohio State University Center for Clinical and Translational Science (CCTS/CTSA) in collaboration with other CTSAs from our “network partners” in the OSU-PDN and the Consortium. The CCTS/CTSA provides consulting services and access to clinical and translational research infrastructure. This unique resource will assist our team in communicating with the CDMC, DSMB and NIDDK central repository. Both research proposals from our network address gaps in knowledge and understanding of chronic pancreatitis, diabetes and pancreas cancer as outlined by the NIDDK- National Commission on Digestive Diseases, and are strategically aligned with the objectives of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC-CCs) (U01).

项目摘要和摘要(初次提交) 慢性胰腺炎和T3cDM的诊断仍然是最大的挑战和 现代胃肠病学中未得到满足的需求。这份来自俄亥俄州的U01申请的重点 美国州立大学将在美国的学术机构之间建立战略联盟。 我们的主要目标是解决该联盟的研究目标和目的，并 被认为是临床中心的。具体来说，我们a)描述了俄亥俄州立大学 胰腺疾病网络(OSU-PDN)，b)提出两项研究报告以供考虑 由财团和c)概述我们的临床和翻译研究基础设施。几个 我们小组在CP和T3cDM方面的关键实验观察证实了[OSU- 1)胰液(PF)和尿液的蛋白质组学分析 (U)在CP受试者中，几种胰液显示有统计学意义的折叠变化 蛋白质-SERPINA5、ANXA5、CST3(候选胰液标志物)和尿蛋白- Cpn2、A1AG1、AMYP(候选尿标记物)与健康对照和2)A 观察到血清胰多肽对混合餐的反应有显著差异。 这可能会将T3cDM与更普遍的T2 DM区分开来。这些初步的 观察是我们研究建议的重点，供财团考虑 督导委员会。我们的临床中心将由俄亥俄州立大学集中协调 大学临床和翻译科学中心(CCTS/CTSA)与 其他CTSA来自我们在OSU-PDN和财团中的“网络合作伙伴”。这个 CCTS/CTSA提供咨询服务以及临床和转化性研究 基础设施。这一独特的资源将帮助我们的团队与疾控中心进行沟通， DSMB和NIDDK中央存储库。来自我们网络的两项研究建议都解决了差距 对慢性胰腺炎、糖尿病和胰腺癌的认识和理解 由NIDDK-国家消化疾病委员会概述，并在战略上 与慢性胰腺炎研究联合会的目标保持一致， 糖尿病和胰腺癌临床中心(CSCPDPC-CCS)(U01)。